Ketamine for Treatment of Alzheimers Disease Related Depression
A legfontosabb adatok
- Ki végzi
- Vanderbilt University Medical Center
- Hol
- Nashville (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 2. fázis
- Résztvevők
- 30 fő, tervezett
- Kezdés
- 2026. dec. 1.
- Várható befejezés
- 2029. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Ketamine and saline
- Active Placebo (Midazolam) Infusion
- A regiszteradat frissítve
- 2026. november 17.
Ki vehet részt
- Életkor
- 60 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Age >= 60 years
- Diagnosis for major depressive disorder meeting DSM5 criteria based on clinical assessment by the study clinician
- MADRS score >= 18
- Clinical diagnosis of MCI or mild dementia due to Alzheimer's Disease
- Quick Dementia Rating System (QDRS) 2-12
- Montreal Cognitive Assessment (MoCA) > 14 at screening
- Positive AD biomarker (CSF p-tau181/Aβ42, tau/Aβ42, Aβ42/40, amyloid PET, Tau PET or clinical plasma assays such (p-tau 217 or 181), consistent with AD criteria
- Stable antidepressant medication regimen for at least 4 weeks prior to the start of infusions with plans to continue on the same medication and dose during the study
- Fluent in English
- Participants must have a study partner who is able to attend study visits and has regular contact with the participant, defined as approximately 5 or more hours per week, distributed across multiple days
- Currently be in active treatment with a Vanderbilt Behavioral Health (VBH) provider or community mental health provider. Care must remain continuous for the duration of ketamine treatment
Ki nem vehet részt
- Prior diagnosis of schizophrenia, bipolar disorder, or personality disorder that would interfere with safely participating in the trial
- Concomitant or past history of psychiatric or neurologic disorder other than those considered to be related to AD (e.g., head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks, hemorrhagic and/or non-hemorrhagic stroke)
- Current use of memantine, unless the participant and their prescribing clinician agree to discontinue for the duration of the trial. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist, like ketamine, and is indicated for moderate to severe dementia - not for MCI or mild dementia as the participants enrolled in our trial. If applicable, memantine must be stopped for at least 4 weeks prior to the start of infusions, and participants must refrain from memantine use for the duration of the study
- Active suicidality or suicide attempt in 3 months prior
- Electroconvulsive therapy or transcranial magnetic stimulation in 2 months prior to enrollment
- Current or planned psychotherapy where the potential participant does not want to pause therapy until 2 weeks after the final infusion
- History of hypersensitivity, allergy, or intolerance of ketamine, midazolam, or clonidine
- Uncontrolled hypertension (systolic > 160mm HG or diastolic pressure > 90 mm HG)
- Unstable angina or recent (6 months) cardiovascular event (e.g., myocardial infarction)
- Clinically significant arrhythmias or other clinically significant abnormalities on ECG at screening (minor abnormalities documented as clinically insignificant by the site PI are allowed)
- Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of study drug (e.g., moderate and/or severe untreated obstructive sleep apnea, stroke, or other cerebrovascular conditions, acute glaucoma), as per the site PI's judgement
- Life expectancy of < 1 year because of terminal illness
- Alcohol or substance use disorder of moderate severity or greater in the last year
- Regular use of naltrexone or benzodiazepines
- Acute grief (<1 month)
Helyszínek itt: Egyesült Államok
- Vanderbilt Psychiatric HospitalNashville, Egyesült ÁllamokContact: Carrie WilliamsToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Dementia is one of the major causes of disability and among older adults globally, with 6.7 million Americans living with Alzheimer's disease. Depression is common in people with cognitive and memory problems.
A teljes eredeti leírásKevesebb
Depression in the elderly increases the risk of disability, medical comorbidity, cognitive impairment, and death. Patients with depression are at an increased risk of worsening cognition. Further, patients with depression are traditionally excluded from therapeutic trials in Alzheimer's Disease and other dementias. Current medications to treat depression in patients with dementia haven't been helpful. Effective approaches to treating depression in dementia are necessary.
Ketamine has been studied extensively for the treatment of depression. It produces a rapid antidepressant effect with improvement of depressive symptoms reported 2 hours after infusion that continues for several days. Due to its rapid action, ketamine has gathered significant public attention. Providers in the community are already administering this drug to patients with dementia based on anecdotal evidence without evidence of its safety or benefit. A fast, safe, and effective treatment of depression may reduce the rate of cognitive decline in patients with dementia and reduce depression burden and improve quality of life and function. As patients with depression are likely unable to receive disease modifying therapies for Alzheimer's Disease (lecanemab or donanemab) rapid improvement of depressive symptoms with ketamine could represent treatment that allows them to be able to receive these therapies faster.
This proposal, will examine the safety, tolerability and feasibility of administering IV ketamine for the treatment of depression in participants with Alzheimer's Disease as well as obtain preliminary data regarding the treatment benefit.
A vizsgálat 2 csoportja
- KetamineA vizsgált kezelés
Kezelés: Ketamine and saline
- Active Placebo (Midazolam)Placebo, összehasonlításként
Kezelés: Active Placebo (Midazolam) Infusion
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2026. november 17.